Barclays
TNXP icon

Barclays’s Tonix Pharmaceuticals TNXP Stock Holding History

Barclays’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90K Sell
6,549
-15,682
-71% -$241K ﹤0.01% 4073
2025
Q4 		$347K Buy
22,231
+9,765
+78% +$180K ﹤0.01% 4056
2025
Q3 		$301K Sell
12,466
-833
-6% -$30.9K ﹤0.01% 4098
2025
Q2 		$478K Buy
+13,299
New +$348K ﹤0.01% 3781
2018
Q2 		– Hold
0
– – – 7281
2018
Q1 		– Hold
0
– – – 7330
2017
Q2 		– Hold
0
– – – 6928
2017
Q1 		– Hold
0
– – – 6975
2013
Q4 		– Hold
0
– -$2K – 7680
2013
Q3 		– Hold
0
– – – 7207

Other funds holding TNXP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Barclays's TNXP Position: Q1 2026 in Review

Barclays reduced its Tonix Pharmaceuticals (TNXP) stake by 71% in Q1 2026, selling an estimated $241K and leaving 6,549 shares worth $90K. The position accounts for ﹤0.01% of the portfolio, ranked #4073.

Barclays first reported a position in TNXP in Q2 2025 and has held it in 4 quarters since. The position peaked at $478K in Q2 2025. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • Barclays held 6,549 shares of Tonix Pharmaceuticals worth $90K as of Q1 2026.
  • Barclays sold 15,682 Tonix Pharmaceuticals shares in Q1 2026, an estimated $241K.
  • Tonix Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4073 holding.
  • Barclays first reported a position in Tonix Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Barclays's Tonix Pharmaceuticals position peaked at $478K in Q2 2025.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.